跳至主要内容
临床试验/NCT04496414
NCT04496414已完成不适用

A Multi-center, Retrospective Registry Study on the Safety of Bactiseal Catheter

Integra LifeSciences Corporation3 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2020年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
3
主要终点
50 Participants With Non-infection Within One Year

研究概览

简要总结

Research Purpose: This study aimed to continue to evaluate safety information from subjects implanted with a catheter (trade name: Bactiseal) produced by Codman & Shurtleff, Inc. of the United States. Device safety would be assessed based on all the adverse events that occurred within one year after the subjects implanted the catheter.

详细描述

This study aimed to continue to evaluate safety information from subjects implanted with a catheter (trade name: Bactiseal) produced by Codman & Shurtleff, Inc. of the United States. Device safety would be assessed based on all the adverse events that occurred within one year after the subjects implanted the catheter.

This study was designed to be single arm, multi-center, and retrospective. A total of 50 patients would be retrospectively enrolled. Information would be collected on adverse events of subjects enrolled within one year after the implantation of the Bactiseal Catheter from August 07, 2018 to Novemver 30, 2020.

The following information would be collected from subjects' medical records or hospitals' databases (if any):

  1. General condition of the subjects
  2. Intraoperative condition and catheter implantation
  3. Information on the shunt product
  4. Adverse events of subjects within one year after the operation and classification of the adverse events
  5. Relevant examinations in case of postoperative infection
  6. Other adverse event-related information (except anticipated adverse events)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • The informed consent was exempted by the Ethics Committee of a research center. Either a subject or his/her legal representative signed the informed consent form (ICF) prior to enrollment.
  • A subject had an indication suitable to use Bactiseal Catheter.
  • A subject received a hydrocephalus shunt at least one year ago.

排除标准

  • A subject didn't have an indication suitable to use the product.
  • A subject was known to be allergic to a component or ingredient of the product to be implanted, including silicone tubing, rifampicin, and clindamycin.
  • According to the comprehensive judgment of an investigator, a subject had an infection of the implant site when the shunt was implanted, such as ventriculitis, meningitis, peritonitis, and local implant skin infection.
  • A subject was simultaneously implanted with another shunt system different from Bactiseal Catheter.
  • A subject had a contraindication of the shunt operation.
  • A subject had uncorrected coagulopathy or any bleeding disorder.

结局指标

主要结局

50 Participants With Non-infection Within One Year

时间窗: 1 year

50 Participants with Non-infection Within One Year

次要结局

  • Type and Incidence of Adverse Events of 50 Subjects Within One Year(1 year)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

Bactiseal Catheter Safety Registry in China | 临床试验